» Articles » PMID: 20472554

Two Modes of Beta-receptor Recognition Are Mediated by Distinct Epitopes on Mouse and Human Interleukin-3

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2010 May 18
PMID 20472554
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

The cytokine interleukin-3 (IL-3) is a critical regulator of inflammation and immune responses in mammals. IL-3 exerts its effects on target cells via receptors comprising an IL-3-specific alpha-subunit and common beta-subunit (beta c; shared with IL-5 and granulocyte-macrophage colony-stimulating factor) or a beta-subunit that specifically binds IL-3 (beta(IL-3); present in mice but not humans). We recently identified two splice variants of the alpha-subunit of the IL-3 receptor (IL-3R alpha) that are relevant to hematopoietic progenitor cell differentiation or proliferation: the full length ("SP1" isoform) and a novel isoform (denoted "SP2") lacking the N-terminal Ig-like domain. Although our studies demonstrated that each mouse IL-3 (mIL-3) R alpha isoform can direct mIL-3 binding to two distinct sites on the beta(IL-3) subunit, it has remained unclear which residues in mIL-3 itself are critical to the two modes of beta(IL-3) recognition and whether the human IL-3R alpha SP1 and SP2 orthologs similarly instruct human IL-3 binding to two distinct sites on the human beta c subunit. Herein, we describe the identification of residues clustering around the highly conserved A-helix residue, Glu(23), in the mIL-3 A- and C-helices as critical for receptor binding and growth stimulation via the beta(IL-3) and mIL-3R alpha SP2 subunits, whereas an overlapping cluster was required for binding and activation of beta(IL-3) in the presence of mIL-3R alpha SP1. Similarly, our studies of human IL-3 indicate that two different modes of beta c binding are utilized in the presence of the hIL-3R alpha SP1 or SP2 isoforms, suggesting a possible conserved mechanism by which the relative orientations of receptor subunits are modulated to achieve distinct signaling outcomes.

Citing Articles

Interleukin-5 and IL-5 receptor in health and diseases.

Takatsu K Proc Jpn Acad Ser B Phys Biol Sci. 2011; 87(8):463-85.

PMID: 21986312 PMC: 3313690. DOI: 10.2183/pjab.87.463.


The role of interchain heterodisulfide formation in activation of the human common beta and mouse betaIL-3 receptors.

Mirza S, Chen J, Murphy J, Young I J Biol Chem. 2010; 285(32):24759-68.

PMID: 20516062 PMC: 2915712. DOI: 10.1074/jbc.M109.097881.

References
1.
Olins P, Bauer S, Sterbenz K, Polazzi J, Caparon M, Klein B . Saturation mutagenesis of human interleukin-3. J Biol Chem. 1995; 270(40):23754-60. DOI: 10.1074/jbc.270.40.23754. View

2.
Murphy J, Metcalf D, Young I, Hilton D . A convenient method for preparation of an engineered mouse interleukin-3 analog with high solubility and wild-type bioactivity. Growth Factors. 2009; 28(2):104-10. DOI: 10.3109/08977190903443048. View

3.
Yao S, Murphy J, Low A, Norton R . 1H, 13C and 15N resonance assignments of a highly-soluble murine interleukin-3 analogue with wild-type bioactivity. Biomol NMR Assign. 2010; 4(1):73-7. DOI: 10.1007/s12104-010-9213-1. View

4.
Murphy J, Young I . IL-3, IL-5, and GM-CSF signaling: crystal structure of the human beta-common receptor. Vitam Horm. 2006; 74:1-30. DOI: 10.1016/S0083-6729(06)74001-8. View

5.
Brown R, Adams J, Pelekanos R, Wan Y, McKinstry W, Palethorpe K . Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat Struct Mol Biol. 2005; 12(9):814-21. DOI: 10.1038/nsmb977. View